What would clearing senescent cells actually change?

You may have heard senolytics described as a way to clear "zombie cells" and slow aging. There is a real research field behind that phrase. The useful question is what has happened when the approach has been tested in people.

In a small liver study, more people on dasatinib plus quercetin had less scarring on biopsy than people on placebo. A bone trial with the same two drugs missed its main goal. The condition, the outcome and the side effects all matter when deciding what a result means. [9] [5]

What are senescent cells?

Senescence is a state in which cells stop dividing. This can help prevent damaged cells from multiplying. Senescent cells can also release signals that affect nearby tissue, and their accumulation is one target of aging research. Senolytics are compounds studied for their ability to selectively kill these cells. [1] [2]

A 2011 experiment used genetically engineered mice with accelerated aging to remove cells carrying a senescence marker. Some age-related problems developed later. That helped establish the biological idea, but it was not a human treatment study. In 2015, researchers identified senolytic effects of dasatinib and quercetin in cell experiments and studied the combination in mice. [1] [2]

What changed in the liver trial?

A double-blind study randomized 31 adults with a form of fatty liver disease called metabolic dysfunction-associated steatohepatitis, or MASH. All had liver scarring. After 21 weeks, 8 of 17 people assigned to dasatinib plus quercetin met the main goal of improving at least one stage of scarring without worsening steatohepatitis. One of 14 assigned to placebo met that goal. [9]

Four people did not finish the trial. When the researchers counted missing biopsies in the way least favorable to treatment, the difference was no longer statistically clear. Fourteen people in the drug group reported adverse events compared with six on placebo. One stopped treatment because of gastrointestinal symptoms and fatigue. A larger, longer study would help establish how often the biopsy improvement lasts and whether it reduces complications of liver disease. [9]

What did the lung, bone and memory studies find?

Pulmonary fibrosis, 2019: fourteen people took part in a short, open-label study of dasatinib plus quercetin. Walking speed, walking distance and chair-rise performance improved from baseline, while lung function did not. One serious adverse event was reported. With no comparison group, the study could not show how much of the change was caused by treatment. Its main purpose was feasibility. [3]

Pulmonary fibrosis, 2023: a later pilot from the same trial program randomized twelve people to the drug combination or placebo. It found no meaningful between-group difference in the exploratory lung, frailty or physical-function measures. The sample was too small to settle efficacy. Researchers recorded 65 non-serious adverse events in the drug group and 22 in the placebo group. A participant could have more than one event. No serious adverse event was attributed to the combination. [4]

Bone metabolism, 2024: an open-label randomized trial studied sixty postmenopausal women over twenty weeks. The primary endpoint, a blood marker of bone breakdown called CTx, did not improve significantly compared with control. A marker of bone formation rose at weeks two and four, but the difference was no longer significant at week twenty. Two participants stopped treatment because of a prolonged QTc interval on an ECG or fatigue and other side effects. [5]

Women with higher baseline levels of a senescence-related marker appeared to respond differently in exploratory analyses. That is a question for the next study to test. It does not establish that treatment prevents fractures or that a blood test can already identify who should receive it. The trial's main result remains important when discussing those subgroup findings. [5]

Alzheimer's disease, 2023: a twelve-week pilot in five people primarily examined whether the drugs reached the central nervous system and whether the study was feasible. Researchers detected dasatinib in the fluid around the brain and spinal cord in four participants. They could not detect quercetin in any of the samples. Prespecified cognitive measures did not change significantly. One exploratory verbal-learning measure worsened, but the study had no control group and was not designed to establish an effect on cognition. [6]

Did researchers find fewer senescent cells in human tissue?

One small study gave dasatinib plus quercetin to 11 people with diabetes and kidney disease. Nine had usable fat samples for tissue staining before and after treatment. In a published correction, researchers reanalysed those paired samples. Fat tissue had fewer cells positive for a senescence marker called p16 after treatment. Their earlier claim about a significant decrease in senescent cells in skin did not hold up. Without a concurrent comparison group, this is a clue about effects in tissue. Whether it improves kidney function is a separate question. [10] [11]

How to put those results in perspective

Cells and animals

Useful for understanding a target and testing an idea. Results do not establish a treatment effect in people.

Early human studies

Can show whether a study is practical and measure short-term responses. Small samples leave substantial uncertainty.

Controlled trials

Help separate treatment effects from other changes. The main outcome matters, including when it is negative.

Patient benefit

Needs evidence about outcomes that matter to patients. These studies do not establish longer human life.

A biomarker is a measurement that helps researchers study a biological process. Improving one measurement does not automatically mean someone will feel better, avoid a fracture or live longer. Our article on epigenetic clocks explores that same distinction with biological age tests.

What is still being studied?

The SToMP-AD registry lists a phase 2 Alzheimer's study as active and not recruiting, with estimated enrollment of 48 and no results posted as of November 9, 2026. That describes ongoing research, not a positive result. Recruitment status and completion estimates can change. [7]

A published protocol describes a placebo-controlled study of fisetin and inflammation markers in adults aged fifty or older. It outlines what the investigators plan to measure. [8]

Has fisetin itself been tested in people?

Yes. A trial in knee osteoarthritis has results posted on ClinicalTrials.gov. Its primary measure was safety. At least one adverse event occurred in 28 of 34 people assessed on fisetin and 33 of 40 on placebo. The trial found no significant advantage for fisetin in the reported comparisons of knee pain or six-minute walking distance. Those results concern that formulation and a specific knee condition. They give no estimate of an effect on human lifespan. [12]

Questions to ask before acting on a claim

For a practical way to assess a paper, read how to read a regenerative medicine study.

Who was studied?

  • Were these cells, animals or people?
  • Did the participants have a condition relevant to you?
  • How many people completed the study?

What changed?

  • Was there a comparison group?
  • Did the primary outcome improve?
  • Was the result a biomarker or a practical health outcome?

What remains open?

  • What adverse events occurred?
  • How long were people followed?
  • Has another study confirmed the finding?

The trials discussed here used screening and monitoring, and several were designed mainly to find out whether larger studies could be done. Their results do not establish a self-treatment schedule or long-term safety. Bring the actual paper to a qualified clinician if you want to understand what it means for your circumstances.

Questions people ask

Do senolytics reverse aging in people?

The studies discussed here do not establish that senolytics reverse aging or extend human life. They test particular drugs in selected groups, often with small samples and short follow-up. A change in a biomarker needs to be distinguished from a change in health.

Did the bone trial work?

The trial did not meet its primary endpoint in the overall group. A bone-formation marker increased early but not at 20 weeks, and exploratory subgroup findings generated questions for further research. The study did not establish fracture prevention.

Is a fisetin supplement equivalent to the treatments studied?

The clinical results depend on the actual compound and condition studied. A trial of fisetin in knee osteoarthritis reported similar rates of adverse events and no significant advantage in knee pain or six-minute walking distance compared with placebo. The separate study of inflammation in older adults is represented here by its published protocol.

What should I ask about a senolytic claim?

Ask for the original study, who took part, the comparison group, the main outcome and the adverse events. Ask whether the finding came from cells, animals or people, and whether it would change a decision relevant to your health.

What to take away

Senolytics are worth following because the idea is being tested in people. Read the full result, including the main outcome, adverse events and limits of the study. That gives you a much better basis for a conversation than the promise of clearing "zombie cells."

The evidence

Sources checked November 9, 2026. The references identify published studies, a corrected report, registry results and protocols. Browse the studies in our Science library.

PRECLINICAL1. Baker DJ et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature (2011). Published study · PubMed 22048312
PRECLINICAL2. Zhu Y et al. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell (2015). Published study · PubMed 25754370
CLINICAL TRIAL3. Justice JN et al. Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. EBioMedicine (2019). Published study · PubMed 30616998
RCT4. Nambiar A et al. Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability. EBioMedicine (2023). Published study · PubMed 36857968
RCT5. Farr JN et al. Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial. Nat Med (2024). Published study · PubMed 38956196
CLINICAL TRIAL6. Gonzales MM et al. Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial. Nat Med (2023). Published study · PubMed 37679434
TRIAL REGISTRY, NO POSTED RESULTS7. Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD). NCT04685590. Status checked November 9, 2026.
STUDY PROTOCOL, NOT RESULTS8. Tavenier J et al. Low-Dose Fisetin Supplementation and Its Association With Chronic Inflammation in Middle-Aged and Older Adults: Study Protocol for a Triple-Blind, Randomised, Placebo-Controlled Trial. Basic Clin Pharmacol Toxicol (2026). Published protocol · PubMed 42633989
Controlled liver trial9. Senolytics dasatinib and quercetin in metabolic dysfunction-associated steatohepatitis: a proof-of-principle randomized, controlled trial. Nat Metab (2026). Publication · PubMed 42823536
Open-label tissue study10. Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine (2019). Publication · PubMed 31542391
Correction11. Corrigendum to 'Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease' EBioMedicine 47 (2019) 446-456. EBioMedicine (2020). Publication · PubMed 31982828 · Corrected analysis (Word)
Registry results12. Senolytic Drugs Attenuate Osteoarthritis-Related Articular Cartilage Degeneration: A Clinical Trial. Fisetin in knee osteoarthritis. NCT04210986 results

This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. The research discussed does not establish a self-treatment protocol. Any treatment decision should be made with a qualified physician. Individual results vary.